Learn About Our Key
Near-Term Milestones
Top line results expected in Q1 2024 for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapyârelated diarrhea.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease